<<

585

Hypochlorhydria, which may be present in patients with also required with calcium -channel blockers, which may membranes for I to 4 weeks after the drug is stopped. Small AIDS, can reduce absorption of itraconazole. In this case increase the risk of congestive heart failure if given together, amounts are distributed into breast milk. absorption may be improved by giving itraconazole with an and nisoldipine in particular is considered contra-indicated. Itraconazole is metabolised in the mainly by acidic drink, such as a cola beverage. Use with the statins is also best avoided because of the risk of P450 isoenzyme CYP3A4. The major metabo­ muscle damage. lite, hydroxyitraconazole, has activity compar­ Breast feeding. Licensed product information does not Reviews of drug interactions vvith azole . able with that of itraconazole. Itraconazole is also excreted recommend breast feeding while receiving itraconazole Baciewicz FA. and lluconazole drug as inactive metabolites in the bile or ; 3 to 18% is although only small amounts of itraconazole are distribu­ Intern Med 1993; 153: 1970-6. excreted in the faeces as unchanged drug. Small amounts 2. Lomae.;;tro BM, on drug interactions with awle ted into breast milk. are eliminated in the stratum corneum and hair. Itracon­ antifungal agents. Ann 1998; 32: 915-28. 3. Venkatakrishnan K, et a!. Effects of the antifungal on oxidative azole is not removed by dialysis. Porphyria. The Drug Database for Acute Porphyria, com­ drug : clinical relevance. Clin 2000; 38: 111- The elimination half-life after a single 100-mg dose has piled by the Norwegian Porphyria Centre (NAPOS) and 80. been reported as 20 hours, increasing to 30 to 40 hours with the Porphyria Centre Sweden, classifies itraconazole as continued use. probably porphyrinogenic; it should be prescribed only for Immunosuppressants. Fatal hepatitis occurred in a 68- compelling reasons and precautions should be considered year-old woman 1 after 2 months of use of itraconazole P.r�p�r<:Jii<:J':lS. in all patients.1 and leflunomide. The authors suggested that the combined hepatotoxicity of both drugs might have accounted for ProprietaryPreparations (details are given in Volume B) l. The Drug Database for Acute Porphyria. Available at http://www. this. drugs-porphyria.org (accessed 14/10/ll) Single-ingredient Preparations. Arg.: Itrac; Micotenk; Nitridazol; l. A, et al. Fatal hepatitis with leflunomide and itraconazole. Am 1 Panastat; Salimidin; Sporanox; Austral.: Sporanox; Austria: 113: 352-3 . Itrabene; Sporanox; Belg.: Sporanox; Braz.: Estiranox; Fungo­ Interactions nax; ltraconolt; Itracotan; Itrahexal; Itralex; Itraspor; Itrazol; -inducing drugs such as , , Metal ions. Didanosine in a formulation containing alu­ Neo Itrax; Sporanox; Spozol; Traconal; Tracozont; Tratzol; , , , , , minium and magnesium ion buffering agents could reduce Traxonol; Canad.: Sporanox; Chile: Itodal; Sporanox; Teramic; or St John's wort may decrease plasma concentrations of the absorption of itraconazole due to the resultant increase China: Mei Fu Sporanox (J!Ji&f=t!i): Yi Qi Kang itraconazole sufficiently to reduce its efficacy. Conversely, in gastric pH. 1 �); Cz. : Cladostad;(9iem): Prokanazol; Sporanox; Denm.: Itrastad; (§Nid­;;;; dazol; Sporanox; Sporanox; Sporanox; Itracolt; enzyme inhibitors such as clarithromycin, erythromycin, I. Moreno F, et al. Itraconazole-didanosine excipient interaction. lAMA Fin.: Fr.: Ger.: 269: Itraconbeta; Itradenn; Sempera; Slro:.; Assosept-S; Bevona­ HIV-protease inhibitors, including -boosted HIV­ 199 3; 1508. Gr.: zole; Brovicton; Deratil; Etrel; Fansidol; Flunol; Fungonazol; protease inhibitors, may increase plasma concentrations of Fungospor; Idranox; Inrozol; Isoflon; Itrabest; Itracon; Itraco­ itraconazole. Use of drugs that reduce stomach acidity, such Antimicrobial Action nal; Itralfa; Itraproton; Itraspor; Itraviron; Itrazol; Laverio; Lor­ as antimuscarinics, antacids, proton pump inhibitors, and Itraconazole is a triazole antifungal drug that in sensitive enzo!; Mesmor; Micronazol; Mycodrox; Neo-Candimyk; Promi­ histamine H -receptor antagonists, may reduce the 2 fungi inhibits cytochrome P450-dependent nox; Soprazon; Sporanox; Sporizole; Stas; Sterginox; Zetilox; absorption of itraconazole. resulting in impairment of ergosterol synthesis in fungal Hong Kong: Aranox; Inox; Itracon; Itranstad; Quali-itrazole; Like other triazole antifungals, itraconazole is a potent Sporacidt; Sporanox; Cladostad; Itraconep; Itragen; cell membranes. It has a slightly wider spectrum of activity Hung.: inhibitor of the cytochrome P450 isoenzyme CYP3A4, and Omicral; Orungal; India: Biospore; Candistat; Canditral; Ful­ than ketoconazole. It is active against Aspergillus spp., may increase plasma concentrations of other drugs reliant cover; Fungicap; Itaspor; Itra; Itracan; Itrazen; Itrole; Indon.: Blastomyces dermatitidis, Candidaspp., Coccidioides immitis, upon it for their metabolism. This increases the risk of Forcanox; Fungitrazol; Furolnokt; Itzol; Mycotrazol; Nufatrac; Cryptococcus neoformans, Epidermophytonspp., Histoplasma adverse effects and such combinations should be given with Petrazole; Sporacid; Sporanox; Sporax; Spyrocon; Trachon; Tra­ capsulatum, Malassezia fu rfu r, Microsporum spp., Paracocci­ caution and careful monitoring, if at all. Drugs so affected cor; Unitrac; Zitrazolt; Irl.: Sporanox; Israel: Itranol; Sporanox; dioides brasiliensis, Sporothrix schenckii, and Trichophyton spp. may include: Ital. : Sporanox; Tranizolo; Trazer; Triasporin; Jpn: Itrizole; Itraconazole also has son1e antiprotozoal activity against antiarrhythmics such as disopyramide, dofetilide and Malaysia: Canditral; Inox; Itracon; Sporanox; Unitrac; Mex.: • Leishmania spp. Carexant; Conamed; Congox; Derusil; Ergospharmat; Fitocyd; quinidine Acquired resistance to itraconazole is rare but ketocon­ Fuzoltec; Imazolt; Iqcona; Isoporum; Isox; Itracosid; Itranax; such as • azole�resistant strains of Candida albicans have been found to Lozartil; Rixtal; Seritral; Silicsan; Sinozol; Solmavin; Sporanox; antiepileptics such as carbamazepine (which in turn • be cross resistant to itraconazole. Steitraz; Trax; Z-Fin; Zitriasol; Zolken; Zotril; Neth.: Trisporal; decreases the concentration of the antifungal, see above) Norw.: Sporanox; NZ: Itcozol; Itrazole; Sporanox; Philipp.: antihistamines such as , mizolastine, and • Microbiological interactions. Synergistic antifungal effects In ox; Sporanox; Pol. : ItraGen; ItraMerck; Orungal; Trioxal; terfenadine were seen in vitro with terbinafine and itraconazole against Port.: Fungizol; Itracic; Sporanox; Unisens; Rus.: Canditral antimalarials such as halofantrine (KaH,[{JIT}Jarr); Irunine (11pyHHH); Itramicol (UrpaM.llKOJI); Itrazol • strains of Candida albicans1 and Scedosporium prolzficans. 2 antimigraine drugs such as , ergo­ (Urpa3oJI); Miconihol (MHKOHHXOJI); Orungal (OpyHrarr); Orun­ • For effects on the antifungal activity of azoles when given metrine, , methylergometrine, and eletriptan gamin (OpyHraMrrH); Orunit (OpyHHT); Rumycoz (PyMHK03); with amphotericin B, see p. 572.3. Teknazol (TeKH

The symbol t denotes a preparation no longer actively marketed 586 Antifun als

fluconazole or itraconazole are usually preferred. It has adverse effects, and lower efficacy. If used as an alterna­ 3. Nguyen M, et al. Infantile hypercalcemia and hypercalciuria: new been recommended that, because of its erratic absorption tive it is given in doses of 400 to 800 mg daily.1 insights into a vitamin D·dependent mechanism and response to ketoconazole treatment. J Pediatr 2010; 157: 296-302. and slow therapeutic response, ketoconazole should not be 1. Chapman SW, et al. Clinical practice guidelines for the management of used for the treatment of life-threatening fungal infections, blastomycosis: 2008 update by the Infectious Diseases Society of Leishmaniosis. Ketoconazole has been tried as an alterna­ including fungal meningitis, or for severe infections in America. Clin Infect Dis2008; 46: 1801-12. Also available at: http://www. joumals.uchicago.edu/doi/pdf/ 10.1086/588300 (accessed 03/07/08) tive to conventional first- and second-line therapy for inununocompromised patients. visceral leishmaniasis (p. 923.1),1.2 although reports of The place of ketoconazole in the treatment of fungal treatment have not all been favourable.'·• infections is discussed in the various sections under Choice Endocrine disorders ond molignont neoplosms. Ketocon­ It has also been tried in cutaneous leishmaniasis of Antifungal, p. 563.1. Ketoconazole has also been used in azole has been reported to impair steroid hormone synth­ (p. 922.1). A cure rate of 70% was reported in over 100 the treatment of some protozoal infections, including esis1 and to blunt the response of cortisone to adrenocorti­ patients with Leishmania major infections treated with oral acanthamoeba infections and leishmaniasis. It has also been cotrophic hormone (ACTH)2 and has been tried in the ketoconazole 200 to 400 mg daily for 4 to 6 weeks. used in the management of acute respiratory distress management of some endocrine disorders. Ketoconazole was not considered to be effective in syodrome, hypercalcaemia, and certain endocrine disorders In Cushing's syndrome (p. 2559.1), ketoconazole in infections due to L. tropica, L. aethiopica,' or L. guyanensis.6 and malignancies. For further information see below. doses of up to 1200 mg dally has been used successfully as Ketoconazole 600 mg daily for 28 days has produced similar The usual oral dose for treatment and prophylaxis of an alternative or adjuvant to definitive therapies such as results to sodium stibogluconate intramuscularly for 20 days fungal infections is 200 mg once daily taken with food. This surgery or radiotherapy. 3·6 in patients with cutaneous leishmaniasis due to L. may be increased to 400 mg daily if an adequate response is Treatment of hirsutism is usually with an panamensis 7 A further comparative study" of 96 patients not obtained; in some infections even higher doses have anti- (see under Cyproterone, p. 2262.1), but being treated for cutaneous leishmaniasis, caused mainly by been used. Treatment should usually be continued until ketoconazole has been tried in small numbers of women at a L. major or L. tropica, found ketoconazole given in doses of symptoms have cleared and cultures have become negative. dose of 300mg daily7 or 400 mg daily,8•9 with variable 600 mg in adults or IOmg/kg in children for 30 days to be Some infections may require several months of treatment results. more effective than 6 to 8 bi-weekly intralesional injections and giving ketoconazole for such prolonged periods may Ketoconazole has been reported to produce a beneficial of meglumine antimonate. In another study! ketoconazole increase the risk of hepatotoxicity. response in some forms of precocious puberty (p. 2254.1) was less effective than sodium stibogluconate when It has been suggested that daily doses of 200 mg should that do not generally respond to gonadorelin analogues; cutaneous leishmaniasis was due to L. braziliensis, but not be exceeded when ketoconazole is given with ritonavir­ cessation of menstruation and regression of pubertal signs in more effective when L. mexicanawas the cause. boosted -protease inhibitors. girlsiO and reduced testosterone secretion and increase in For detailsHIV of doses in children, see below. 1. Wall JP, et al. Ketoconazole in treatment of visceral leishmaniasis. Lancet adult height in boys11·13 has been noted in small numbers of 1990; 330: 81D-1 1. Ketoconazole is applied topically as a 2% cream in the patients studied. 2. Wali JP, et al. Ketoconazole in the treatment of - and treatment of candida! or dermatophyte infections of the pentamidine-resistant Kala-azar. J Infect Dis 1992; 166: 215-16. The anti-androgenic effects of ketoconazole have also skin, or in the treatment of pityriasis versicolor. It is used 3. Sundar S, et al. Ketoconazole in visceral leishmaniasis. Lancet 1990; 336: prostatic cancer 1582-3. once or twice daily and continued for at least a few days been found useful in the management of 4. Rashid JR, et al. The efficacy and safety of ketoconazole in visceral (p. 712.3) in selected patients, !4-ls although there have been after the disappearance of symptoms. A foam containing 2% leishmaniasis. East Afr Med J 1994; 71: 392-5. some concernsabout its tolerability, 17 and it is not generally ketoconazole applied twice daily for 4 weeks may be used in 5. Weinrauch L, et al. Ketoconazole in cutaneous leishmaniasis. Br J the treatment of seborrhoeic dermatitis. A shampoo used as a first-line treatment. Dermatol l987; 117: 666-7. containing 1 or 2% ketoconazole is also used; it is applied Ketoconazole was ineffective in suppressing postoper­ 6. Dedet J-P, et al. Failure to cure Leishmania brazilieruis guyanensis ative erection in patients undergoing penile reconstructive cutaneous leishmaniasis with oral ketoconazole. Trans R Soc Trop Med twice weekly for 2 to 4 weeks (or occasionally longer) in the Hyg 1986; 80: 176. surgery; 19 it has been tried with prednisone for the treatment of dandruff or seborrhoeic dermatitis. The 2% 7. Saenz RE, etal. Efficacy of ketoconazole against Leishmania braziliensis shampoo is used once daily for up to 5 days in pityriasis management of recurrent ischaemic priapism.20 panamensis cutaneous leishmaniasis. Am J Med 1990; 89: 147-55. versicolor. For prophylaxis of seborrhoeic dermatitis the 2% 1. Pont A, et al. Ketoconazole blocks adrenal steroid synthesis. Ann Intern 8. Salmanpour R, et al. Comparative study of the efficacy of oral ketoconazole with intra-lesional meglumine antimoniate (Glucantime) shampoo is used once every 1 to 2 weeks; for prophylaxis of Med 1982; 97: 370-2. 2. White MC, Kendall-Taylor P. Adrenal hypofunction in patients taking for the treatment of cutaneous leishmaniasis. J Dermatol Treat 2001; 12: pityriasis versicolor it may be used once daily for a ketoconazole. Lancet 1985; i: 44-5. 159-62. 9. Navin et al. Placebo-controlled clinical trial of sodium stibogluoonate maximum of 3 days before exposure to sunshine. 3. Winquist EW, et al. Ketoconazole in the management of paraneoplastic TR, (Pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Cushing's syndrome secondary to ectopic adrenocorticotropin produc­ Gucitemala. J Infect Dis 1992; 165: 528-34. Administration in children. In infants and children, keto­ tion. J Clin Oncol 1995; 13: 157-64. 4. Estrada J, et al. The long-term outcome of pituitary irradiation after conazole may be used topically for the treatment of fungal unsuccessful transsphenoidal surgery in Cushing's disease. N Eng!J Med skin infections sintilarly to in adults. Oral use should be 1997; 336: 172-7. Adverse Effects restricted to situations where other antifungals cannot be 5. Berwaerts JJ, et al. Corticotropin-dependent Cushing's syndrome in

All cross-references refer to entries in Volume A 587

5. Pillans PI, et al. Hyponatraemia and in a patient taking trations of isoniazid and rifampicin may also be reduced by zole; Fulkit; Funazolet; Fungicide; Funginoc; Fungizole; ketoconazole. Lancet 1985; 821-2. i: ketoconazole. Hyphoral; Jacanzole; Jcanzole; K to Z; Ke-Toza; Kenazol; Keta­ 6. McCance DR et al. Acute hypoadrenalism and hepatotoxicity after fung; Keto; Ketocare; Ketoco; Ketocure; Ketonex; Ketopil; treatment with ketoconazole. Lancet 1987; 573. Ketoconazole inhibits certain hepatic oxidase enzymes, i: Ketovate; Ketoz; Ketozoe; Ketozole; Kezole; Kiton; Koiz; KZ; 7. Best TR, et al. Persistent adrenal insufficiency secondary to low-dose especially the cytochrome P450 isoenzyme CYP3A4, in a ketoconazole therapy. Am J Med 1987; 82: 676-80. similar way to itraconazole (p. 585.1) and similar care KZL; Nizol; Nizral; Novale; Ocana; Indon.: Anfuhext; Dermar­ 8. Khosla S, et al. Adrenal crisis in the setting of high-dose ketoconazole al; Dexazol; Dysfungalt; Fexazol; Formyco; Funet; Fungasol; should be taken to avoid adverse effects due to increased therapy. Arch InternMed 1989; 149: 802-4. Fungoral; Grazol; Interzol; Ketomed; Lusanoc; Micoticumt; plasma concentrations of the interacting drugs. Muzoral; Mycodenn; Mycoral; Mycozid; Nizol; Nizoral; Nofung; A -like reaction may occur in patients taking Effects onthe liver. Hepatic adverse reactions to oral keto­ Picamic; Profungal; Solinfec; Sporex; Thicazol; Wizol; Zoloral; ketoconazole after drinking alcohol. The efficacy of oral Zoralin; Zumazolt; Ketopine; Ketozol; Nizoral; conazole are well known.'· 4 Transient minor elevations of Irl.: Israel: liver enzymes without clinical signs or symptoms of contraceptives may be reduced. Ketozol; Nizoral; Ital.: Asquam; Nizoral; Triatop; Malaysia: For reviews of drug interactions with azole antifungals, hepatic disease occur in about 10% of patients and may Dezor; Diazon; Fungazol; Funginox; Ketozotan; Kezoral; Larry; occur at any stage of treatment. Although this reaction is see Itraconazole, p. 585.2. Nizoral; Pristine; Pristinex; Yucomy; Mex. : Akorazolt; Biozoral; not usually clinically important it may signal the onset of Conazol; Cremosan; Ergomicon; Eurolat; Fomiral; Fungipar; Fungoral; Fungosinet; Hispazzont; Honzil; Ketofar; Ketomed; more serious hepatic injury and indicates the need for Antimicrobial Action Ketomizol; Ketoril; Konaderm; Konaturil; Lizovag; Messelzol; close monitoring of liver function. Symptomatic hepatic Ketoconazole is an imidazole antifungal that interferes with Mi-Ke�Sons; Micoser; Micozol; Mycocil; Mycodib; Nastil; reactions are much rarer (less than 0.1% of patients) but ergosterol synthesis and therefore alters the permeability of Nazolfarm; Nazoltec; Nizoral; Onofin-K; Prenalon; Remecon; are potentially fatal. There is usually a hepatocellular pat­ the cell membrane of sensitive fungi. It is reported to be Strizolet; Termizol; Tiniasil; Tiniazol; Toconal; Tolcrem; Tomi­ tern of damage and sometimes cholestasis. Patients at fungistatic at concentrations achieved clinically. Ketocon­ ko; Triatop; Neth.: Nizoral; Norw.: Fungoral; Konazalt; NZ: increased risk of hepatic injury include those with a his­ azole has a wide spectrum of antimicrobial activity Daktagold; Ketopine; Nizoral; Sebizole; Philipp.: Conatabt; tory of , those aged over 50, especially including activity against Blastomyces dennatitidis, Candida Dezor; Donaxene; Fungizol; Ketovid; Konazole; Kazee; Nizoral; women, and those requiring prolonged treatment. It is spp., Coccidioides immitis, Epidennophyton floccosum, Histoplas­ Reduff; Pol.: Fungorest; Nizoral; Noell; Zoxinat; Port.: Farmor­ important to monitor liver function during treatment as ma capsulatum, Malassezia spp., Microsporum canis, Para­ ol; Nizale; Nizoral; Tedol; Rus.: Fungistab (

The symbol denotes a preparation no longer actively marketed t